| INTRODUCTION
Ulcerative colitis is characterised by a chronic disease course commonly complicated by intermittent flares with still some patients remaining refractory to current therapeutic strategies. Finally, 10 to 15 per cent of patients with ulcerative colitis eventually require surgery either by failing medical therapy or by developing dysplasia.
The surgical treatment of choice for the majority of these patients is the proctocolectomy followed by a construction of ileal pouch-anal anastomosis (IPAA). 1, 2 Whilst one half of patients after IPAA due to ulcerative colitis remain in remission without any further medication and report a sufficient control regarding bowel habits, the other half of patients develop a nonspecific inflammation of the ileal reservoir, a so-called pouchitis. [3] [4] [5] Symptoms of pouchitis include an increased stool frequency of liquid stools, abdominal cramping and high urgency. [6] [7] [8] [9] Ten to fifteen per cent of patients with acute pouchitis will develop chronic pouchitis which is defined by symptom duration of more than 4 weeks. These patients require long-term treatment. 10 Based on the response to antibiotic therapy patients may be antibioticresponsive, antibiotic-dependent (with the need for a permanent treatment to maintain remission) or not responding to antibiotic treatment. This subgroup of patients suffers from antibiotic-refractory pouchitis and should be treated with a combined antibiotic treatment, 11-14 budesonide 15, 16 or the TNF antibodies infliximab or adalimumab. [17] [18] [19] [20] With the help of these drugs 60%-80% of patients with refractory pouchitis achieve clinical response or remission.
Although a variety of other agents has been assessed in small trials (eg, ciclosporin enemas, 21 alicaforsen enemas 22 ) still 1%-2% of patients end up with permanent ileostomy. 4 The pathophysiology of pouchitis though being the most common long-term complication after IPAA is still not completely under-
stood. An increased bacterial concentration and dysbiosis in the ileal reservoir seems to be one of the main contributors. [23] [24] [25] [26] The role of bacteria is further underlined by the good efficacy of antibiotic treatment in active pouchitis and the maintenance of remission by probiotics. [27] [28] [29] [30] Dysbiosis finally contributes to the attraction of leucocyte adhesion by integrin-MAdCam interaction. 31, 32 Given the role of bacteria on the one hand, this role of integrins on the other hand has been additionally studied in some animal models of inflammatory bowel disease (IBD). For example, b7-integrin deficiency abrogated colitis development in a TNF dependent model of Crohn 0 s disease.
With respect to the neo-anatomy of the pouch consisting of terminal ileum these results were confirmed in other animal studies and were mainly seen in gut associated lymphoid tissue of the small intestine (eg, peyer patches of the ileum). 
25%
. 34, 35 Based on the above mentioned details of pouchitis pathophysiology, the use of vedolizumab in pouchitis seems rational.
The excellent safety data for vedolizumab [35] [36] [37] and its benefit on health related quality of life 38 further support its use in chronic pouchitis as a long-term therapy in some cases of pouchitis is mandatory. To the best of our knowledge, only four brief [39] [40] [41] [42] reports present data from a total of seven patients treated with vedolizumab in case of refractory pouchitis so far. 
| PATIENTS AND METHODS
This retrospective uncontrolled multicentre study was performed in 10 German centres for inflammatory bowel disease (university hospitals, hospitals, medical practices). All of these centres belong to the German IBD study group, where all data were collected and anonymised. Data were collected from January 2016 to December 2016 in a descriptive manner using one single clinical report form (CRF).
All patients were diagnosed according to standard endoscopic, histological and radiological criteria and infectious complications were 
| Ethical considerations
The study has been conducted according to the Declaration of Helsinki. Each patient gave written informed consent prior to study entry. The study was approved by the local Ethics Committee (University of Luebeck, 15-131A).
| Statistical analysis
Results are described as mean, median and range. Statistical differences were calculated using a one sided t test and a level of 0.05 or less was considered to be significant. Results were calculated using the SPSSWIN program.
3 | RESULTS
| Medical history and concomitant medication
Twenty patients were included in our study (12 males) (details are also shown in Table 1 ). The median age at first diagnosis of ulcerative colitis was 22.5 years (range 7-49), the median time to proctocolectomy was 10 years (range 0-24 years). Prior to IPAA 80% of the patients were treated with thiopurines, 25% received methotrexate, 85% had systemic steroids and 75% of all patients had been given a treatment with at least one TNF antibody. One fourth of the patients were treated with calcineurin inhibitors. Due to a refractory disease course pouch formation was performed. To the best of our knowledge no patient in our cohort underwent surgery due to neo- Week F I G U R E 3 Pouch function represented by the Pouchitis Disease Activity Index (PDAI) before and after vedolizumab treatment in TNF antibody naive and TNF antibody experienced patients, respectively. Clinical activity was assessed by the Pouchitis Disease Activity Index (PDAI) alongside the treatment period with vedolizumab (also see Figure 2 ). Figure 3 illustrates the median PDAI at wk 0 and 14 in our cohort. The two Whisker plots on the left represent the data in patients being never treated with TNF antibodies after the onset of pouchitis, on the right data is presented of patients who already were treated with a TNF antibody due to pouchitis prior the use of vedolizumab Eight patients received antibiotic co-medication with doxycycine, ciprofloxacin or metronidazole in parallel with vedolizumab, at week 14 only two patients still received these antibiotics. Loperamide and tincture of opium were needed in six patients at the start of vedolizumab. This was reduced to a number of four patients at week 14.
Only three patients received systemic steroids in parallel at week 14, at the beginning, five patients were on systemic steroids (Table 2 ). to lower the PDAI and improve symptoms in patients with pouchitis. 28 The efficacy with regards to the endoscopic response and side effects might be slightly better with ciprofloxacin. The probiotic preparation VSL#3 has been shown effectiveness for maintenance of remission and to prevent the first episode after pouch construction. 44, 45 However, 10 to 15% of patients with acute pouchitis develop a chronic or refractory course of the disease. In these cases an antibiotic combination therapy (metronidazole and ciprofloxacin or rifaximin and ciprofloxacin) or oral budesonide is suggested with 75%-80% of patients responding. 15 Unfortunately, only small trials have . Thereby, a score of "0" represents no improvement of symptoms, a score of "1" represents mild, of "2" moderate or of "3" excellent improvement of symptoms. The mean score was 1 at wk two and increased to a mean score of 1.9 at wk 6. The mean score at wk 10 was 2.1 and the final score at wk 14 was 2. | 585 investigated this benefit and only for a short period of time (mostly 4-8 weeks).
Patients with relapsing disease are not easy to treat and a variety of approaches have been assessed so far. Budesonide or ciclosporin enemas were successful in small trials with mild disease courses. 16, 21 Oral azathioprine is a therapeutic option as it is in budesonide dependent patients. 46 Two studies examined the role of infliximab in chronic pouchitis. In the first study 28 patients with refractory pouchitis were included and over 80% of the patients responded within 10 weeks of treatment. The PDAI decreased from 9.0 to 4.5 points.
However, only half of the patients still had a clinical response after 20 months and five patients needed permanent ileostomy. 17 The second study reported unsatisfactory results with only one-third of the patients having a complete clinical response at week 52. 
